Want to use our logo?

Download the ICS Branding Pack

ICS Background

Dr Tomohiro Matsuo
Department of Urology, Nagasaki University School of Medicine

ICS 2019

Open Discussion ePoster Session 18 E-Poster 2 304 The effects of visceral fat amount and psoas major muscle volume on lower urinary tract symptoms

Open Discussion ePoster Session 18 E-Poster 2 317 Effect of Salt Intake Reduction on Overactive Bladder

ICS 2018

Podium Short Oral Session 15 Overactive Bladder 1 269 Relationship between excess visceral fat accumulation and the development and severity of overactive bladder

Podium Short Oral Session 29 Interstitial Cystitis / Bladder Pain Syndrome 2 610 Possible usefulness of blood inflammatory marker C-reactive Protein as a biomarker for Hunner lesions in interstitial cystitis

Podium Short Oral Session 33 Overactive Bladder 2 648 Efficacy of tadalafil monotherapy and associations between changes in subjective overactive bladder symptoms and changes in oxidative stress in patients with lower urinary tract symptoms

ICS 2017

Podium Short Oral Session 13 Pelvic Pain 251 Significance of C-reactive protein an inflammatory marker in interstitial cystitis

Podium Short Oral Session 29 Urethra and Nocturia 517 Influence of amount of urinary calcium excretion in adults on urinary symptoms including nocturia

Podium Short Oral Session 29 Urethra and Nocturia 518 Can salt intake restriction be one of the treatment options for nocturia?

ICS 2016

Open Discussion ePoster Session 19 Open Discussion ePosters 363 The measurement of vaginal pressure and transversus abdominis muscle thickness may be a predictor for pelvic organ prolapse

Non Discussion Abstract Session 32 Non Discussion Abstracts 851 The efficacy of Yokukansan, Japanese traditional herbal medicine, on nocturia due to night-time awakening

ICS 2015

Open Discussion ePoster Session 25 Open Discussion ePoster 381 The usefulness of ultrasound measurements of transverse abdominal muscle thickness in patients with pelvic organ prolapse

Podium Session 2 Nocturia Effects of daily salt intake on urinary symptoms: a comparison between patients with hypertension and normal blood pressure

ICS 2014

Open Discussion Poster Session 11 Lower Urinary Tract Symptoms in Women 116 Preoperative measurement of the bladder wall thickness may be useful to predict postoperative improvement of overactive bladder symptoms in patients with overactive bladder associated with pelvic organ prolapse.

Open Discussion Poster Session 37 Pharmacology 573 Oral administration of prosultiamine improved the symptoms in patients with overactive bladder associated with HTLV-1-related myelopathy/tropical spastic paraparesis, and also reduced urinary biomarkers.

ICS 2013

Non Discussion Poster Session 34 575 The influence of administration of a1-adrenergic receptor antagonist (urapidil) on oral dryness in female patients with urinary disorders

Non Discussion Abstract Session 35 Read By Title 693 Questionnaire survey on possible oral dryness for comparisons among three a1-adrenergic receptor antagonists (naftopidil vs. tamsulosin vs. silodosin)

Non Discussion Abstract Session 35 Read By Title 696 Administration of prosultiamine for HTLV-1-associated myelopathy may improve not only voiding symptoms but also storage symptoms by decreasing urinary nerve growth factor levels

ICS 2012

Podium Poster Session 11 Rehabilitation and Conservative Treatments I 113 Nocturnal catheterization in patients with clean intermittent catheterization impairs their quality of life and is associated with sleep disorder

Podium Poster Session 23 Neurourology: Clinical III 204 New Treatment Strategy for Neurogenic Bladder in Patients with HTLV-1-associated Myelopathy

ICS 2011

Non Discussion Poster Session 29 298 Symptoms of Urination Are Unlikely to Alleviate Even after Transurethral Prostatectomy in BPH/LUTS Patients with Urinary Bladder Weight of 65 g or more

Non Discussion Poster Session 29 305 Evaluation of Clinical Efficacy of Naftopidil in Benign Prostatic Hyperplasia: Switching from alpha1A Receptor Blocker in Poor Responders

Non Discussion Abstract Session 31 Read by Title 641 Evaluation of Combination Therapy (75 mg/day Naftopidil plus 30 mg/day Urapidil) in Patients with BPH/LUTS Poorly Responding to alpha1 Blocker Monotherapy

Tomohiro Matsuo

Member

Profession:Clinical Researcher
Qualifications:PhD
Privacy:
You must be logged in to view this contact
Sign-in to ICS
NO DISCLOSURE STATEMENT RECORDED
VOLUNTARY